BPI
TVTX icon

BFC Planning, Inc.’s Travere Therapeutics TVTX Stock Holding History

BFC Planning, Inc.’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81K Hold
67
– – ﹤0.01% 2776
2026
Q1 		$1.99K Sell
67
-2
-3% -$60 ﹤0.01% 2598
2025
Q4 		$2.64K Buy
+69
New +$2.24K ﹤0.01% 2554

Other funds holding TVTX

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BFC Planning, Inc.'s TVTX Position: Q2 2026 in Review

BFC Planning, Inc. held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 67 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2776.

BFC Planning, Inc. first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 322 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • BFC Planning, Inc. held 67 shares of Travere Therapeutics worth $3.81K as of Q2 2026.
  • BFC Planning, Inc. left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #2776 holding.
  • BFC Planning, Inc. first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 322 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.